PDCD1 and neoplasm: An ongoing clinical trial (NCT02834013) evaluating the combination of anti-CTLA-4 (ipilimumab) and anti-PD-1 (nivolumab) blockade in rare tumor types including metaplastic breast cancer have been conducted [303].